• español
  • English
  • français
  • Deutsch
  • português (Brasil)
  • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Parcourir

    Tout UVaDOCCommunautésPar date de publicationAuteursSujetsTitres

    Mon compte

    Ouvrir une session

    Statistiques

    Statistiques d'usage de visualisation

    Compartir

    Voir le document 
    •   Accueil de UVaDOC
    • PUBLICATIONS SCIENTIFIQUES
    • Institutos de Investigación
    • Instituto de Biología y Genética Molecular (IBGM)
    • IBGM - Artículos de revista
    • Voir le document
    •   Accueil de UVaDOC
    • PUBLICATIONS SCIENTIFIQUES
    • Institutos de Investigación
    • Instituto de Biología y Genética Molecular (IBGM)
    • IBGM - Artículos de revista
    • Voir le document
    • español
    • English
    • français
    • Deutsch
    • português (Brasil)
    • italiano

    Exportar

    RISMendeleyRefworksZotero
    • edm
    • marc
    • xoai
    • qdc
    • ore
    • ese
    • dim
    • uketd_dc
    • oai_dc
    • etdms
    • rdf
    • mods
    • mets
    • didl
    • premis

    Citas

    Por favor, use este identificador para citar o enlazar este ítem:http://uvadoc.uva.es/handle/10324/32543

    Título
    Influence of HLA Matching on the Efficacy of Allogeneic Mesenchymal Stromal Cell Therapies for Osteoarthritis and Degenerative Disc Disease
    Autor
    García-Sancho Martín, Francisco JavierAutoridad UVA Orcid
    Sánchez García, Ana María de los ÁngelesAutoridad UVA Orcid
    Vega Castrillo, AurelioAutoridad UVA
    Noriega González, David CésarAutoridad UVA
    Nocito Colón, Mercedes
    Año del Documento
    2017
    Editorial
    Lippincott, Williams & Wilkins
    Descripción
    Producción Científica
    Documento Fuente
    Transplantation Direct, 2017 - Volume 3 - Issue 9 - p e205
    Résumé
    The necessity for more effective therapies for chronic osteoarticular diseases has led to the development of treatments based on mesenchymal stem cells (MSCs), the natural precursors of musculoskeletal tissue. Treatments with autologous MSCs yielded excellent results, with nearly 70% improvement of pain and disability in osteoarthritis and degenerative disc disease. Using allogeneic MSCs is logistically more convenient and would widen the pool of eligible patients, but potential immune rejection should be considered. In this context, MSCs are purportedly immune evasive and better tolerated than other cell types. Methods We used samples collected during the performance of 2 randomized clinical trials using allogeneic bone marrow MSCs for treatment of osteoarthritis (NCT01586312) and degenerative disc disease (NCT01860417). Serum samples were used to determine anti-HLA antibodies, whereas either blood or MSC samples were used for HLA typing of recipients and donors, respectively. Algofunctional indexes were used as indicators of clinical evolution, and the correlation between the number of donor-host HLA mismatches and the efficacy of treatment was determined. Results Immune response was weak and transient, with reactivity decaying during the first year. Consistently, better donor-recipient HLA matching did not enhance efficacy. Conclusions This lack of reactivity is presumably due to the cooperation of 2 factors, (1) downregulation of the host immune responses by the transplanted MSCs and (2) effective insulation of these cells inside the articular cavity or the intervertebral disc, respectively. Interestingly, better HLA matching did not enhance efficacy. These observations have medical relevance as they support the clinical use of allogeneic cells, at least as a single-dose administration. Multiple-dose applications will require further research to exclude possible sensitization.
    Palabras Clave
    HLA
    Antígeno leucocitario humano
    Human leukocyte antigen
    ISSN
    2373-8731
    Revisión por pares
    SI
    DOI
    10.1097/TXD.0000000000000724
    Patrocinador
    Red de Terapia Celular of the Instituto de Salud Carlos III (RD16/0011/0003) and Centro en Red de Medicina Regenerativa de Castilla y León
    Version del Editor
    www.transplantationdirect.com
    Idioma
    eng
    URI
    http://uvadoc.uva.es/handle/10324/32543
    Derechos
    openAccess
    Aparece en las colecciones
    • IBGM - Artículos de revista [78]
    Afficher la notice complète
    Fichier(s) constituant ce document
    Nombre:
    Transplant-Direct-Influence-HLA.pdf
    Tamaño:
    140.2Ko
    Formato:
    Adobe PDF
    Thumbnail
    Voir/Ouvrir
    Attribution-NonCommercial-NoDerivatives 4.0 InternationalExcepté là où spécifié autrement, la license de ce document est décrite en tant que Attribution-NonCommercial-NoDerivatives 4.0 International

    Universidad de Valladolid

    Powered by MIT's. DSpace software, Version 5.10